LY 2780301

Drug Profile

LY 2780301

Alternative Names: LY S6KAKT1; LY-2780301

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Institut Paoli-Calmettes; Institute Gustave-Roussy
  • Class Antineoplastics
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 16 Apr 2016 Interim pharmacokinetics and drug interaction data from a phase Ib trial in breast cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 23 Dec 2015 Phase-Ib development for Solid tumours and Non-Hodgkin's lymphoma (Combination therapy, Late-stage disease, Metastatic disease) is ongoing in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top